AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx

AbbVie has entered a major collaboration with ADARx Pharmaceuticals, paying $335 million upfront to co-develop next-generation small interfering RNA (siRNA) therapeutics1 5.

The deal covers several key disease areas:
neuroscience, immunology, and oncology, with both preclinical and future programs included2 3 5.

The agreement could ultimately be worth several billion dollars to ADARx through milestone payments and royalties in addition to the $335 million upfront3 5.

siRNA therapeutics offer a gene-silencing approach by interfering directly with messenger RNA, halting the production of disease-causing proteins—potentially delivering long-lasting effects without genome editing4 5.

AbbVie brings expertise in antibody engineering and tissue delivery, while ADARx contributes proprietary RNA platform technology and discovery capabilities4 5.

The collaboration is expected to accelerate the advancement of precision gene silencing therapies, potentially impacting therapeutic areas such as chronic autoimmune disease and cancer4 5.